Reduction of protein kinase A-mediated phosphorylation of ATXN1-S776 in Purkinje cells delays onset of Ataxia in a SCA1 mouse model
- PMID: 29758256
- PMCID: PMC6028938
- DOI: 10.1016/j.nbd.2018.05.002
Reduction of protein kinase A-mediated phosphorylation of ATXN1-S776 in Purkinje cells delays onset of Ataxia in a SCA1 mouse model
Abstract
Spinocerebellar ataxia type 1 (SCA1) is a polyglutamine (polyQ) repeat neurodegenerative disease in which a primary site of pathogenesis are cerebellar Purkinje cells. In addition to polyQ expansion of ataxin-1 protein (ATXN1), phosphorylation of ATXN1 at the serine 776 residue (ATXN1-pS776) plays a significant role in protein toxicity. Utilizing a biochemical approach, pharmacological agents and cell-based assays, including SCA1 patient iPSC-derived neurons, we examine the role of Protein Kinase A (PKA) as an effector of ATXN1-S776 phosphorylation. We further examine the implications of PKA-mediated phosphorylation at ATXN1-S776 on SCA1 through genetic manipulation of the PKA catalytic subunit Cα in Pcp2-ATXN1[82Q] mice. Here we show that pharmacologic inhibition of S776 phosphorylation in transfected cells and SCA1 patient iPSC-derived neuronal cells lead to a decrease in ATXN1. In vivo, reduction of PKA-mediated ATXN1-pS776 results in enhanced degradation of ATXN1 and improved cerebellar-dependent motor performance. These results provide evidence that PKA is a biologically important kinase for ATXN1-pS776 in cerebellar Purkinje cells.
Keywords: ATXN1-S776; Ataxia; Ataxin-1; Cerebellum; PKA; Phosphorylation; Polyglutamine; Protein stability; Purkinje cells; SCA1; cAMP-dependent protein kinase.
Copyright © 2018 The Authors. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
None declared
Figures
Similar articles
-
Modulation of ATXN1 S776 phosphorylation reveals the importance of allele-specific targeting in SCA1.JCI Insight. 2021 Feb 8;6(3):e144955. doi: 10.1172/jci.insight.144955. JCI Insight. 2021. PMID: 33554954 Free PMC article.
-
Phosphorylation of ATXN1 at Ser776 in the cerebellum.J Neurochem. 2009 Jul;110(2):675-86. doi: 10.1111/j.1471-4159.2009.06164.x. Epub 2009 May 15. J Neurochem. 2009. PMID: 19500214 Free PMC article.
-
Dopamine D2 receptor signaling modulates mutant ataxin-1 S776 phosphorylation and aggregation.J Neurochem. 2010 Aug;114(3):706-16. doi: 10.1111/j.1471-4159.2010.06791.x. Epub 2010 Apr 30. J Neurochem. 2010. PMID: 20477910 Free PMC article.
-
Spinocerebellar Ataxia Type 1: Molecular Mechanisms of Neurodegeneration and Preclinical Studies.Adv Exp Med Biol. 2018;1049:135-145. doi: 10.1007/978-3-319-71779-1_6. Adv Exp Med Biol. 2018. PMID: 29427101 Review.
-
SCA1-phosphorylation, a regulator of Ataxin-1 function and pathogenesis.Prog Neurobiol. 2012 Dec;99(3):179-85. doi: 10.1016/j.pneurobio.2012.04.003. Epub 2012 Apr 16. Prog Neurobiol. 2012. PMID: 22531670 Free PMC article. Review.
Cited by
-
A Structural Study of the Cytoplasmic Chaperone Effect of 14-3-3 Proteins on Ataxin-1.J Mol Biol. 2021 Sep 17;433(19):167174. doi: 10.1016/j.jmb.2021.167174. Epub 2021 Jul 21. J Mol Biol. 2021. PMID: 34302818 Free PMC article.
-
Pathogenic mechanisms underlying spinocerebellar ataxia type 1.Cell Mol Life Sci. 2020 Oct;77(20):4015-4029. doi: 10.1007/s00018-020-03520-z. Epub 2020 Apr 18. Cell Mol Life Sci. 2020. PMID: 32306062 Free PMC article. Review.
-
Modulation of ATXN1 S776 phosphorylation reveals the importance of allele-specific targeting in SCA1.JCI Insight. 2021 Feb 8;6(3):e144955. doi: 10.1172/jci.insight.144955. JCI Insight. 2021. PMID: 33554954 Free PMC article.
-
Patient-Specific iPSCs-Based Models of Neurodegenerative Diseases: Focus on Aberrant Calcium Signaling.Int J Mol Sci. 2022 Jan 6;23(2):624. doi: 10.3390/ijms23020624. Int J Mol Sci. 2022. PMID: 35054808 Free PMC article. Review.
-
Widespread alternative splicing dysregulation occurs presymptomatically in CAG expansion spinocerebellar ataxias.Brain. 2024 Feb 1;147(2):486-504. doi: 10.1093/brain/awad329. Brain. 2024. PMID: 37776516 Free PMC article.
References
-
- Orr HT, Chung MY, Banfi S, Kwiatkowski TJ, Servadio A, Beaudet AL, McCall AE, Duvick LA, Ranum LP, Zoghbi HY. Expansion of an unstable trinucleotide CAG repeat in spinocerebellar ataxia type 1. Nat Genet. 1993;4:221–226. - PubMed
-
- Schut J, Haymaker W. A pathologic study of five cases of common ancestry. JNeuropath Clin Neurol. 1951;1:183–213. - PubMed
-
- Matilla-Dueñas A, Goold R, Giunti P. Clinical, genetic, molecular, and pathophysiological insights into spinocerebellar ataxia type 1. Cerebellum. 2008;7:106–114. - PubMed
-
- Xia H, Mao Q, Eliason SL, Harper SQ, Martins IH, Orr HT, Paulson HL, Yang L, Kotin RM, Davidson BL. RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia. Nat Med. 2004;10:816–820. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Miscellaneous